We use cookies to give you the best online experience. Please see our cookie policy here.
Please let us know if you agree to all of these cookies..
We are dedicated to developing next generation immunotherapies to transform the lives of patients with cancer.
F-star’s wholly owned pipeline generates first and best-in-class drug candidates that work with patients’ immune systems to stop tumors from evading the body’s defense mechanisms.
F-star’s proprietary tetravalent bispecific antibody format ensures focused, potent and safe activation of the patient’s immune system.
Our most advanced drug candidate, aiming to rescue checkpoint inhibitor failures, in a proof-of-concept Phase 2 trial in patients with head and neck cancer, who have developed acquired resistance to PD-1/PD-L1 immunotherapies.